Navigation Links
Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
Date:5/7/2008

y authorities regarding clinical studies of Genz-112638; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

(617) 768-6579 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
2. MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook
3. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
4. Longs Reports Preliminary March Retail Drug Store Sales
5. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
6. Conseco Reports Preliminary Fourth Quarter and Year-End Results
7. NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares
8. Longs Reports Preliminary February Retail Drug Store Sales
9. CRH Medical reports preliminary year end results
10. Sunrise Reports Preliminary Selected Financial and Operating Data for Fourth-Quarter 2007
11. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ead to new therapies for preterm labor , ... say they,ve found the switch that activates the u...a finding that may lead to therapies for preterm l...ds the protein IP on the surface of these uterine ...ing pregnancy. , But researchers from Dartmout...
(Date:11/21/2008)...a., Nov. 21 During a m...Edward G. Rendell today remembered Lieutenant Gove...an important partner in public service, and a tire... , "As the first woman elected lieutenant gove...vant," said Governor Rendell. "Her family and her ...
(Date:11/21/2008)... Banzel proved effective against Lennox-Gastaut sy...ws) -- A new drug called Banzel (rufinamide) has b...vere form of epilepsy called Lennox-Gastaut syndro...d Friday. , The approval was based on results o...ts ages 4 to 30. Compared to patients who took a p...
(Date:11/21/2008)...lders Intend To Vigorously Protect Investment And ...ov. 21 Dr. Stephen Joff...ndment to their Schedule 13D with the U.S. Securit... filed a 13D disclosing ownership of 11.4% of LCA-...LasikPlus fixed-site laser vision correction cente...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...loped a micro capsule coated with silicon, which c...ection.This microchip works by absorbing nutrient...ucing cells.Some diabetics have to inject insulin ...r blood sugar levels. The device is being develope...
...e of disability in the United States, affects more...ances in treatment options and educational efforts...d and poorly treated in the US. In fact, a recent ...ns with serious mental illness fail to receive ade...
...hat children have the greatest increase in bone mi...Children who do not take enough exercise are in da...ys the study. Many fail to strengthen up their ske...efore puberty, which is critical to building healt...
...evel electromagnetic fields (EMF) at home could do...national study has found. //The three-year review ...n Non-Ionizing Radiation Protection (ICNIRP) by si...nstitutions around the world. Leukemia, which deve...
Other Medicine News:
(Date:11/20/2008)...all/ -- PAREXEL International Corporation (Nasdaq:...ices provider, today announced that it has opened ...ulting and clinical research capabilities. With th...ations throughout five important biopharmaceutical...ntina, Brazil, Chile, and Mexico. This expansion f...
(Date:11/19/2008)...Newswire-FirstCall/ -- Amgen,(Nasdaq: AMGN ) an...diary of,Takeda Pharmaceutical Company Limited (T... Phase 3 MONET1 trial evaluating motesanib (AMG 70... for the first-line treatment of,advanced non-sma...uspended,following a planned safety data review o...
(Date:11/19/2008)...swire/ -- Biotech scientists increasingly are appl...to better understand the effects of novel drug can...netic Engineering & Biotechnology News ( GEN ...a new compound,s mechanism of action and eventuall...cording to the November 15 issue of GEN . ( http:...
(Date:11/18/2008)...rstCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a spec...opment Company,and Sosei Group Corporation ("Sos...ional biopharmaceutical company, today announce th...re-clinical efficacy data for NSL-043/SD118.,This...europathic pain and has,successfully completed Ph...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 1AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 2AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 4AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 5AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 6AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 7AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 8AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9173 9China Information Security Technology Inc Issues Guidance 26 Discuss Outlook for 2009 29750 1China Information Security Technology Inc Issues Guidance 26 Discuss Outlook for 2009 29750 2China Information Security Technology Inc Issues Guidance 26 Discuss Outlook for 2009 29750 3China Information Security Technology Inc Issues Guidance 26 Discuss Outlook for 2009 29750 4China Information Security Technology Inc Issues Guidance 26 Discuss Outlook for 2009 29750 5KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10 Q 29749 1KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10 Q 29749 2KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10 Q 29749 3KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10 Q 29749 4Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 1Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 2Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 3Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 4Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 5Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 29745 6
... 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. , a...therapeutics for the treatment of cancer and infla...eclinical results for its Aurora,kinase - angiogen...ed during oral and poster presentations by EntreMe...scovery Conference,being held May 31 - June 1, 200...
... International Conference on Avian,Influenza at Fr...Newswire-FirstCall/ -- Very low doses of,Novavax I...on,against a lethal challenge of live H5N1 viruses...day at the Second International,Conference on Avia...6 microgram doses of Novavax,s,virus-like particle...
Other Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4
Vannas Capsulotomy scissors angled forward
Gills-Vannas side angled capsulotomy flat handle scissors
Vannas angled capsulotomy flat handle scissors
No. 1. 30 mm conventional blades. Thin well-rounded tips.
Medicine Products: